-
December 17, 2010
Sanofi-aventis and Merck KGaA Sign Agreement to Jointly Investigate Novel Combinations Against Cancer
Sanofi-aventis announced today that sanofi-aventis U.S. Inc. has signed a worldwide research and developement agreement with Merck KGaA, Darmstadt, Germany, under which Merck's division Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells.
-
December 14, 2010
Sanofi-aventis and Oxford University Collaborate to Conduct Oncology Research in India
Sanofi-aventis and Oxford University have entered into an agreement to conduct multi-phase oncology clinical and translational research with INDOX, India's leading academic oncology network.
-
November 26, 2010
Sanofi-aventis scoopes inaugural Corporate Responsibility Award at Pharmaceutical Marketing Excellence Awards 2010
The Pharmaceutical Marketing Excellence Awards (PMEA) has awarded leading pharmaceutical company sanofi-aventis its Corporate Responsibility Award.
-
November 12, 2010
Sanofi-aventis and The Cedar Centre Join Forces to Send an Uplifting Message in Support of World Diabetes Day 2010
On Friday 12th November 2010, sanofi-aventis and The Cedar Centre will mark World Diabetes Day, celebrated on 14th November, by asking people all over the world to help create the world's biggest e-balloon release at www.balloons-4-diabetes.com.
-
November 05, 2010
Sanofi-aventis partners in European Atrial Fibrillation Research Consortium
Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the "European Network for Translational research in Atrial Fibrillation (AF)", (EUTRAF), which has been awarded a €12 million grant to engage in atrial fibrillation (AF) research.
-
October 26, 2010
Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN β).
-
October 15, 2010
Teriflunomide Successfully Reduces relapses and is Well Tolerated in Multiple Sclerosis Patients
Sanofi-aventis announced today the results from the two year Phase III TESMO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).
-
October 10, 2010
New report shows better management of Atrial Fibrillation in Wales could save NHS Wales millions of pounds every year
A new report, released this week by the Atrial Fibrillation Association (www.atrialfibrollation.org.uk) and the Stroke Association in Wales (www.stroke.org.uk) calls for improvements in the detection and management of atrial fibrillation, the most common heart rhythm disorder ('arrhythmia') seen in clinical practice, in Wales.
-
October 10, 2010
Final Results from Phase II Study Confirm BSI-201 (Iniparib) Prolongs Survival in Metastatic Triple Negative Breast Cancer
Sanofi-aventis and its fully owned subsidiary, BiPar Sciences, today announced that final results from a randomised Phase II clinical trial confirmed that treatment with BSI-201 (iniparib*) in combination with gemcitabine/carboplatin results in a significant improvement in overall survival and a high rate of clinical response in women with metastatic triple negative breast cancer (mTNBC).
-
October 01, 2010
Landmark study published in The Lancet shows 30% improvement in overall survival with cabazitaxel in men with advanced prostate cancer resistant to other therapy
Sanofi-aventis announced today final Phase III study results published in The Lancet for their novel taxane therapy, cabazitaxel. Cabazitaxel is the first treatment within a Phase III study to increase overall survival in men with metastatic hormone-refractory prostate cancer (mHRPC), which is progressing despite docetaxel chemotherapy.
-
September 23, 2010
Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in Oncology
Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute (DFCI) in Boston Massachusetts, announced today that they have entered into a collaboration and licence agreement to identify novel oncology targets for the development of new therapeutic agents directed at such targets and related biomarkers.
-
September 22, 2010
Clinical Update on Tamaris Phase III Trial for NV1FGF
Sanofi-aventis announced today that the Phase III TAMARIS trial evaluating the investigational angiogenic therapy NV1FGF (riferminogen pecaplasmid) did not meet its primary endpoint.
-
September 13, 2010
SMC Approves Multaq® (Dronedarone) for Use in Scotland
Sanofi-aventis is delighted that the Scottish Medicines Consortium (SMC) has advised NHS Boards and Area Drug and Therapeutic Committees that Multaq® (dronedaraone) is accepted for use within NHS Scotland.
-
September 01, 2010
Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalisation
Sanofi-aventis announced today that results from the RealiseAF (Real-life global survey evaluating patients with Atrial Fibrillation) registry show that control of atrial fibrillation (AF) was not achieved in more than 40 percent of the AF patients included in this 10,000 patient cross-sectional registry, as presented today during the European Society of Cardiology Congress in Stockholm, Sweden.
-
August 29, 2010
Multaq® First-line Option in New 2010 ESC Guidelines for the Management of Arial Fibrillation
Sanofi aventis announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial Fibrillation (AF) have been released and recommended that Multaq® (dronedarone) should be used for maintenance of sinus rhythm as a first-line treatment option in all patients with paroxysmal and persistent AF.
-
August 29, 2010
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Sanofi-aventis announced today that it has submitted a non-binding proposal to acquire Genzyme in an all-cash transaction valued at approximately $18.5 billion.
-
August 25, 2010
Multaq® approved for use in England and Wales - final guidance received from NICE
Sanofi-aventis is delighted that NICE has published final guidance on the use of Multaq® (dronedarone) for the treatment of atrial fibrillation (AF).
-
July 19, 2010
Jevtana® (cabazitaxel) Injection Now Available in the U.S.
Jevtana plus prednisone is the first and only therapy approved for patients with metastatic hormone-refractory prostate cancer previously treated with docetaxel-based therapy.
-
July 01, 2010
Sanofi-aventis and JDRF Form Partnership to Improve Therapies, Work Toward Cure for Type 1 Diabetes
Sanofi-aventis and the Juvenile Diabetes Research Foundation (JDRF) announced today a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease - both those living with the disease and the newly diagnosed - as well as preventing diabetes in those at risk.
-
June 30, 2010
Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical company
Sanofi-aventis announced today that it has signed an agreement for the acquisition of TargeGen Inc., a privately held US biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukaemia, lymphoma and other haematological malignancies and blood disorders.
-
June 25, 2010
Sanofi-aventis and Metabolex enter into an Exclusive Worldwide Licensing Agreement for a Novel Oral Antidiabetic to treat Type II Diabetes
Sanofi-aventis and Metabolex announced today a global licensing agreement on MBX-2982, an oral agent, GPR119 receptor agonist, for the treatment of Type II Diabetes.
-
June 22, 2010
Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics
Sanofi-Aventis and Regulus Therapeutics Inc announced today that they have entered into a global strategic alliance to discover, develop, and commercialize microRNA therapeutics.
-
June 17, 2010
Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.
-
June 04, 2010
Sanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in Oncology
Sanofi-aventis and Ascenta Therapeutics, a US Biopharmaceutical Company in Malvern, Pennsylvania, announced today the signature of an exclusive global collaboration and licensing agreement on a number of compounds that could restore tumor cell apoptosis.
-
May 28, 2010
Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in Japan
Sanofi-aventis and Nichi-Iko Pharmaceutical Co., Ltd. announced today that they have signed an agreement to establish a new joint venture, called sanofi-aventis Nichi-Iko K.K., in order to develop a generic business in Japan.
-
May 27, 2010
Updated Phase 3 Survival Results with Cabazitaxel in Patients with Advanced Hormone-Refractory Prostate Cancer, Presented at ASCO
Sanofi-aventis announced today the updated results from the Phase 3 trial, TROPIC, that demonstrated the investigational drug cabazitaxel plus prednisone/prednisolone, significantly improved overall survival, versus an active chemotherapy combination of mitoxantrone plus prednisone/prednisolone, in patients with metastatic hormone-refractory (castration-resistant) prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.
-
May 26, 2010
Sanofi-aventis Establishes Strategic Alliance with MIT's Center for Biomedical Innovation
Sanofi-aventis announced today a strategic alliance agreement with the Massachusetts Institute of Technology Center for Biomedical Innovation, which will be known as the sanofi-aventis Biomedical Innovation Program (SABIP).
-
May 25, 2010
Sanofi-aventis Wins the 2010 Global Business Coalition Core Competence Award for its Innovative Malaria Access to Medicines Program
Sanofi-aventis announced today that it has been awarded the 2010 Global Business Coalition Core Competence Award, for its innovative Malaria Access to medicines partnership program with the Drugs for Neglected Diseases Initiative (DNDi).
-
May 19, 2010
Sanofi-aventis to Reinforce its Consumer Health Care Platform in Poland
Sanofi-aventis and Nepentes S.A. announced today that Sanofi-Aventis sp. z o.o., a subsidiary of sanofi-aventis, Nepentes S.A. and its controlling shareholders have entered into a definitive agreement under which Sanofi-Aventis sp. z o.o. launched a public tender for 100 percent of the outstanding shares of Nependes S.A., a Polish manufacturer of pharmaceuticals and dermocosmetics, listed on the Warsaw Stock Exchange.
-
May 17, 2010
Combined General Shareholder Meeting of May 17, 2010
The Combined General Shareholder Meeting was held today at the Palais de Congres in Paris.
-
May 17, 2010
Sanofi-aventis Annouces the Creation of the Sanofi Espoir Corporate Foundation
Sanofi-aventis announced today the creation of the Sanofi Espoir Corporate Foundation, dedicated to implementing health and solidarity programs worldwide.
-
May 12, 2010
Sanofi-aventis Initiates 10,000 Patient Study with Multaq® in Permanent Atrial Fibrillation
Sanofi-aventis announced today the initiation of a multinational randomized, double-blind Phase lllb trial, PALLAS, to assess the potential clinical benefit of Multaq® (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events.
-
May 03, 2010
Sanofi-aventis and Glenmark Pharmaceuticals Sign License Agreement on Novel Agents to treat Chronic Pain
Sanofi-aventis announced today that it has entered into a license agreement with Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), for the development and commercialization of novel agents to treat chronic pain.
-
April 30, 2010
Change in sanofi-aventis Executive Committee
Sanofi-aventis announced today that Laurence Debroux, Senior Vice President, Chief Strategic Officer and member of the Executive Committee, has decided to leave the Group to pursue another professional challenge as of July 1, 2010.
-
April 29, 2010
Q1 2010: A good first quarter
Commenting on the Group's performance in Q1 2010, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "During this first quarter, our growth platforms delivered double-digit growth enhanced by recent targeted acquisitions and A/H1N1 vaccine sales".
-
April 23, 2010
Sanofi-aventis Announces Court Decision Resolving Eloxatin® U.S. Patent Litigation
Sanofi-aventis announced today that Sun Pharmaceuticals will be required to cease selling its infringing generic version of Eloxatin® (oxaliplatin) on June 30, 2010 by order of the U.S. District Court for the District of New Jersey.
-
April 15, 2010
Once Daily Lixisenatide (AVE 0010) Given as Monotherapy Successfully Meets Phase III Study Endpoints in Diabetes
Sanofi-aventis announced today that the results of the first, placebo-controlled study of the GetGoal Phase III clinical trial program showed lixisenatide (AVE0010), a once daily GLP-1 agonist, significantly reduced HbA1c vs. placebo with more patients achieving HbA1c<7% and improved glycemic control in adult patients with type 2 diabetes.
-
April 12, 2010
Sanofi Pasteur Partners with U.S. Naval Medical Research Center to Advance Development of Travelers' Diarrhea Vaccine
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) to develop a promising new bacterial vaccine against enterotoxigenic Escherichia coli (ETEC).
-
April 08, 2010
Sanofi-aventis and CureDM Sign Exclusive Worldwide License Agreement on Novel Regenerative Compound to Treat Diabetes
Sanofi-aventis and CureDM Group Holdings, LLC, announced today a global license agreement on a novel human peptide, PancreateTM, which could restore a patients' ability to produce insulin and other pancreatic hormones in both type 1 and type 2 diabetes.
-
April 06, 2010
Sanofi-aventis makes updated settlement announcement regarding Eloxatin® U.S. Patent litigation
Sanofi-aventis announced today that it has settled U.S. patent infringement suits related to certain generic versions of Eloxatin® (oxaliplatin) with additional defendants involved in the litigation.
-
April 05, 2010
Sanofi-aventis Amends Its Alliance Agreement with Warner Chilcott Regarding Actonel® (risedronate sodium) in the United States and Puerto Rico
Sanofi-aventis announced today that it has amended its global collaboration agreement with Warner Chilcott plc regarding Actonel® (risedronate sodium) tablets in the United States and Puerto Rico. Under this amendment, Warner Chilcott will assume full responsibility for the commercialization and management of Actonel® in the United States and Puerto Rico, including sales, marketing, distribution and local R&D decisions. All other aspects of the global collaboration agreement remain in effect.
-
March 30, 2010
Multaq® available in the UK for treatment of atrial fibrillation
Sanofi-aventis today announced the UK availability of Multaq® (dronedarone), one of the major therapeutic innovations in the field of atrial fibrillation (AF) in approximately 20 years.
-
March 05, 2010
Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer
Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overal survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy. The TROPIC trial compared the combination of cabazitaxel plus prednisone/prednisolone to the active agent mitoxantrone plus prednisone/prednisolone.
-
March 02, 2010
NHS Barnet Takes Steps towards Good Heart Health for Barnet Residents
NHS Barnet, with sanofi-aventis, today launches a pilot health screening programme targeting Barnet residents most at risk of heart attack and stroke. Part of the national NHS Health Check programme, the three-month pilot aims to identify people with an increased risk of cardiovascular disease and help them make lifestyle changes to avoid developing heart problems in the future.
-
January 21, 2010
Sanofi-aventis and employees unite for the victims of Haiti
In the face of the unprecedented earthquake that hit the island of Haiti, sanofi-aventis has committed 1 million Euros in financial aid to long-term reconstruction initiatives and the rehabilitation of the population of Haiti.
